Results 1 to 5 of 15

Federal Circuit Upholds Jury Award, Weighs in on Willfulness Standard, in Adynovate® Dispute

USA - March 30 2021 According to the Federal Circuit, $173 million was the right damages award for almost three years of patent infringement resulting from Baxalta’s…

Jordan Engelhardt, Aron Fischer

Sandoz Petitions the Supreme Court for Review of Enbrel® Patent License

USA - March 8 2021 The fight over proposed Enbrel® (etanercept) biosimilar Erelzi® continues. Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (“Sandoz”) recently…

Jordan Engelhardt

Magistrate Judge Reyes Recommends Dismissal of DJ Action Against Assignee That Never Owned The Patent-In-Suit

USA - March 2 2021 On February 9, 2021, United States Magistrate Judge Ramon E. Reyes, Jr. (E.D.N.Y.) recommended that Sell Below Cost USA LLC’s (“Sell Below”) DJ…

Lewis V. Popovski

Federal Circuit Axes Amgen Antibody Patents, Finding Lack of Enablement

USA - February 18 2021 The Federal Circuit considered its 35 U.S.C. § 112 enablement case law and found that “the enablement inquiry for claims that include functional…

Andrew D. Cohen

FDA Approves Breyanzi®—A New Biologic for Treating Large B-Cell Lymphoma

USA - February 9 2021 On February 5, 2021, the FDA approved Juno Therapeutics, Inc.’s Breyanzi® (lisocabtagene maraleucel) for “treatment of adult patients with relapsed…

Jordan Engelhardt